CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy

doi:10.3748/wjg.119588

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 25

This Article

(15)

(17)

(0)

(9)

(256)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jul 7, 2026; 32(25): 119588
Published online Jul 7, 2026. doi: 10.3748/wjg.119588

Full Size Figure Download Figure

Figure 4 Kaplan-Meier curves for overall survival and progression-free survival of patients treated with locoregional-bevacizumab-immunotherapy. A and B: Overall survival (OS; A) and progression-free survival (PFS; B) in patients stratified into different groups according to the Simple-CRAPT-M model; C and D: Subgroup analysis showing OS (C) and PFS (D) in patients receiving different bevacizumab-based immune therapies and stratified into different groups according to the Simple-CRAPT-M model.

Citation: Zheng ZH, Xiao R, Liu N, He BY, Yu W, Wu ZS, Chen MS, Mei J, Hu DD, Guo RP. CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy. World J Gastroenterol 2026; 32(25): 119588
URL: https://www.wjgnet.com/1007-9327/full/v32/i25/119588.htm
DOI: https://dx.doi.org/10.3748/wjg.119588

Zheng ZH, Xiao R, Liu N, He BY, Yu W, Wu ZS, Chen MS, Mei J, Hu DD, Guo RP. CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy. World J Gastroenterol 2026; 32(25): 119588 [DOI: 10.3748/wjg.119588]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.